Nyxoah - Asset Resilience Ratio
Nyxoah (NYXH) has an Asset Resilience Ratio of 12.40% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Nyxoah balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Nyxoah's Asset Resilience Ratio has changed over time. See Nyxoah shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Nyxoah's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Nyxoah.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €11.61 Million | 12.4% |
| Total Liquid Assets | €11.61 Million | 12.40% |
Asset Resilience Insights
- Moderate Liquidity: Nyxoah has 12.40% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Nyxoah Industry Peers by Asset Resilience Ratio
Compare Nyxoah's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Alcon AG
SW:ALC |
Medical Instruments & Supplies | 0.26% |
|
iRay Technology Co Ltd
SHG:688301 |
Medical Instruments & Supplies | 0.68% |
|
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN |
Medical Instruments & Supplies | 29.19% |
|
Jiangsu Nanfang Medical
SHG:603880 |
Medical Instruments & Supplies | 2.27% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 6.36% |
|
I.Ceram SA
PA:ALICR |
Medical Instruments & Supplies | -1.61% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 4.42% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 51.82% |
Annual Asset Resilience Ratio for Nyxoah (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Nyxoah.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 32.43% | €51.37 Million ≈ $60.06 Million |
€158.41 Million ≈ $185.19 Million |
+3.32pp |
| 2023-12-31 | 29.11% | €36.14 Million ≈ $42.25 Million |
€124.16 Million ≈ $145.15 Million |
-23.59pp |
| 2022-12-31 | 52.69% | €76.97 Million ≈ $89.98 Million |
€146.07 Million ≈ $170.77 Million |
-- |
| 2021-12-31 | 0.00% | €0.00 ≈ $0.00 |
€170.83 Million ≈ $199.72 Million |
-- |
About Nyxoah
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgi… Read more